SCHEMBL2353433

SCHEMBL2353433

Cc1ccc(C)c([Si](O[Si](c2cc(C)ccc2C)(c2cc(C)ccc2C)c2cc(C)ccc2C)(c2cc(C)ccc2C)c2cc(C)ccc2C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 3/20 0.36
CYP2A6 P11509 2/20 0.36
TP53 P04637 2/20 0.36
ACHE P22303 3/20 0.34
TAAR1 Q96RJ0 1/20 0.34
HSD17B10 Q99714 2/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
NQO2 P16083 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
CYP3A4 P08684 1/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9463221 0.75 TDP1 (0.44) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL13027083 0.74 ALDH1A1 (0.39) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL843553 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL16707371 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL380345 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL1315699 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL1686686 0.73 TDP1 (0.48) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL7028012 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL842483 0.73 TDP1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53
SCHEMBL1686690 0.73 ALDH1A1 (0.42) TDP1ALDH1A1CYP1A2CYP2A6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049689-B1 NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE BI WANLI (US) 2011-12-21 EP claimed
US-12006311-B2 Compounds for use in preventing or treating cancer FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) 2024-06-11 US disclosed
WO-2024083861-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF SELABTEC SCIENCES, SLU (ES) 2024-04-25 WO disclosed
EP-4356909-A1 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF Selabtec Sciences, SLU (ES) 2024-04-24 EP disclosed
EP-3271468-B1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) 2022-12-14 EP disclosed
CN-107849594-B Deamination of organophosphorus nucleosides 科技学专业学院有限公司 2022-01-18 CN disclosed
CN-106566855-B Nucleic acid amplification using reversibly modified oligonucleotides 苏州新海生物科技股份有限公司 2021-11-09 CN disclosed
US-20210230150-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER AMIRA THERAPEUTICS, S.L. (ES) 2021-07-29 US disclosed
EP-3813832-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) 2021-05-05 EP disclosed
EP-3268353-B1 PYRAZOLYL DERIVATIVES AS PEST CONTROL AGENTS BAYER ANIMAL HEALTH GMBH (DE) 2020-09-09 EP disclosed
EP-1052264-B1 Process for the synthesis of nucleoside analogs PFIZER PROD INC (US) 2005-03-23 EP disclosed
EP-1412346-B1 METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES BAYER CROPSCIENCE AG (DE) 2005-03-09 EP disclosed
EP-1089988-A4 FLUOROPHENYL RESIN COMPOUNDS AVENTIS PHARM PROD INC (US) 2005-01-19 EP disclosed
US-20040242858-A1 Method for producing novel spinosyn derivatives BAYER CROPSCIENCE AG (DE) 2004-12-02 US disclosed
EP-1412346-A1 METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES Bayer CropScience AG (DE) 2004-04-28 EP disclosed
WO-2003010155-A1 METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES BAYER CROPSCIENCE AG (DE) 2003-02-06 WO disclosed
US-6271370-B1 REACTING 2',3'-O-ALKYLIDENE .BETA.-FURANOSYL HALIDE COMPOUND WITH HETEROCYCLE HAVING RING NITROGEN CAPABLE OF FORMING COVALENT BOND WITH ANOMERIC CARBON OF FURANOSE OR FURANOSE ANALOG IN DIMETHYL SULFOXIDE IN PRESENCE OF STRONG BASE PFIZER INC 2001-08-07 US disclosed
EP-1089988-A1 FLUOROPHENYL RESIN COMPOUNDS Aventis Pharmaceuticals Products Inc. (US) 2001-04-11 EP disclosed
EP-1052264-A2 Process for the synthesis of nucleoside analogs Pfizer Products Inc. (US) 2000-11-15 EP disclosed
WO-1999067228-A1 FLUOROPHENYL RESIN COMPOUNDS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242858-A1 Method for producing novel spinosyn derivatives COX15, SYVN1, CYP51A1 TDP1 1403/4885ALDH1A1 1286/4885CYP1A2 124/4885
US-20210230150-A1 COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER UGT1A3, UGT1A1, UGT1A6 TDP1 1650/4885ALDH1A1 14/4885CYP1A2 34/4885
US-12006311-B2 Compounds for use in preventing or treating cancer UGT1A3, UGT1A1, UGT1A6 TDP1 1650/4885ALDH1A1 14/4885CYP1A2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.